Werewolf Therapeutics, Inc.

NasdaqGS:HOWL Stock Report

Market Cap: US$18.5m

Werewolf Therapeutics Management

Management criteria checks 3/4

Werewolf Therapeutics' CEO is Dan Hicklin, appointed in Oct 2017, has a tenure of 8.67 years. total yearly compensation is $1.60M, comprised of 39.6% salary and 60.4% bonuses, including company stock and options. directly owns 1.33% of the company’s shares, worth $246.52K. The average tenure of the management team and the board of directors is 3.1 years and 6.6 years respectively.

Key information

Dan Hicklin

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage39.63%
CEO tenure8.7yrs
CEO ownership1.3%
Management average tenure3.1yrs
Board average tenure6.6yrs

Recent management updates

Recent updates

Analysis Article • May 14

Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 14

Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Jul 31

Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Jul 01

Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1

Summary Werewolf Therapeutics, Inc. is an early-stage biotech focusing on cytokine therapy for cancer treatment. The Pipeline update includes positive results for WTX-124 in clinical trials and promising data for WTX-330. Financially, the company has a decent cash position for now, but may need to address cash burn rate in the near future. Read the full article on Seeking Alpha
Analysis Article • Jun 04

Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Unfortunately for some shareholders, the Werewolf Therapeutics, Inc. ( NASDAQ:HOWL ) share price has dived 34% in the...
Seeking Alpha • Apr 04

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

Summary Werewolf Therapeutics, Inc. develops modified cytokines for cancer treatment, including WTX-124, a modified IL-2, and WTX-330, a modified IL-12. Xilio Therapeutics out-licensed their modified IL-12 to Gilead, but I wouldn't be surprised if Werewolf Therapeutics also has a competitive modified IL-12, with WTX-330. Werewolf Therapeutics is reporting data from its clinical trials of WTX-124 and WTX-330 this half (H1'24), providing near-term catalysts. Read the full article on Seeking Alpha
Analysis Article • Feb 07

Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Werewolf Therapeutics, Inc. ( NASDAQ:HOWL ) shares have continued their recent momentum with a 27% gain in the last...
Analysis Article • Jan 19

Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Dec 09

There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise

Werewolf Therapeutics, Inc. ( NASDAQ:HOWL ) shares have had a really impressive month, gaining 28% after a shaky period...
Analysis Article • Sep 30

Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates

Werewolf Therapeutics, Inc. ( NASDAQ:HOWL ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • Aug 13

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Werewolf Therapeutics, Inc. ( NASDAQ:HOWL ) just released its latest second-quarter results and things are looking...
Analysis Article • May 06

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jan 27

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Oct 24

We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jul 08

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Mar 24

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 09

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...

CEO Compensation Analysis

How has Dan Hicklin's remuneration changed compared to Werewolf Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$56m

Dec 31 2025US$2mUS$633k

-US$61m

Sep 30 2025n/an/a

-US$73m

Jun 30 2025n/an/a

-US$73m

Mar 31 2025n/an/a

-US$72m

Dec 31 2024US$3mUS$608k

-US$71m

Sep 30 2024n/an/a

-US$62m

Jun 30 2024n/an/a

-US$54m

Mar 31 2024n/an/a

-US$42m

Dec 31 2023US$1mUS$583k

-US$37m

Sep 30 2023n/an/a

-US$37m

Jun 30 2023n/an/a

-US$41m

Mar 31 2023n/an/a

-US$50m

Dec 31 2022US$2mUS$530k

-US$54m

Sep 30 2022n/an/a

-US$60m

Jun 30 2022n/an/a

-US$62m

Mar 31 2022n/an/a

-US$115m

Dec 31 2021US$2mUS$498k

-US$202m

Sep 30 2021n/an/a

-US$205m

Jun 30 2021n/an/a

-US$197m

Mar 31 2021n/an/a

-US$127m

Dec 31 2020US$3mUS$425k

-US$28m

Compensation vs Market: Dan's total compensation ($USD1.60M) is above average for companies of similar size in the US market ($USD647.55K).

Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.

CEO

Dan Hicklin (62 yo)

8.7yrs
Tenure
US$1,596,355
Compensation

Dr. Daniel J. Hicklin, also known as Dan, Ph D., Founded Werewolf Therapeutics, Inc. in October 2017 and has been its President and Chief Executive Officer since August 2019. He serves on its Board of Dire...

Leadership Team

NamePositionTenureCompensationOwnership
Daniel Hicklin
Founder8.7yrsUS$1.60m1.33%
$ 246.5k
Michael Urban
VP of Finance3.1yrsno data0.011%
$ 2.0k
Steven Bloom
Chief Business Officer1.2yrsno datano data
3.1yrs
Average Tenure
62yo
Average Age

Experienced Management: HOWL's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Daniel Hicklin
Founder8.7yrsUS$1.60m1.33%
$ 246.5k
Luke Evnin
Independent Chairman of the Board8.7yrsUS$88.69kno data
Michael Sherman
Independent Director5.1yrsUS$71.44k0%
$ 0
Anil Singhal
Independent Director1.3yrsUS$95.32kno data
Charles Craik
Member of Scientific Advisory Boardno datano datano data
Vijay Kuchroo
Member of Scientific Advisory Boardno datano datano data
Briggs Duncan W. Morrison
Director6.6yrsUS$56.44k0.032%
$ 5.9k
Karl Wittrup
Member of Scientific Advisory Boardno datano datano data
Michael Atkins
Member of Scientific Advisory Board & Independent Director7.8yrsUS$111.94k0.030%
$ 5.5k
Meeta Chatterjee
Independent Director4.7yrsUS$63.19k0%
$ 0
Dario Vignali
Member of Scientific Advisory Boardno datano datano data
6.6yrs
Average Tenure
68yo
Average Age

Experienced Board: HOWL's board of directors are considered experienced (6.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/14 05:57
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Werewolf Therapeutics, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Maneka MirchandaneyEvercore ISI
Andres MaldonadoH.C. Wainwright & Co.